Incidence and susceptibility to therapy-related myeloid neoplasms

Chemico-Biological Interactions

Volumn 184, Issue 1-2, 2010, Pages 39-45

  Leone, Giuseppe ^a   Fianchi, Luana ^a   Pagano, Livio ^a   Voso, Maria Teresa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Detoxification; DNA repair; Secondary leukemogenesis; Therapy related myeloid neoplasms

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; AZATHIOPRINE; BENZENE; BLEOMYCIN; CARCINOGEN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MYELOPEROXIDASE; NITROSOUREA DERIVATIVE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TEMOZOLOMIDE; TENIPOSIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 11Q; CHROMOSOME 21Q; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; DETOXIFICATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA REPAIR; DRUG DOSE ESCALATION; ENVIRONMENTAL EXPOSURE; ENZYME POLYMORPHISM; GENETIC VARIABILITY; GERM CELL TUMOR; HODGKIN DISEASE; HUMAN; LEUKEMIA; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; OCCUPATIONAL EXPOSURE; SURVIVAL TIME; THERAPY EFFECT; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; BENZENE; DISEASE SUSCEPTIBILITY; DNA TOPOISOMERASES, TYPE II; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY;

EID: 77950630063     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.12.013     Document Type: Article

References (50)

1. Ng A.K., Travis L.B. Subsequent malignant neoplasms in cancer survivors. Cancer J. 2008, 14:429-434.
2. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., Harris N.L., Le Beau M.M., Hellstrom-Lindberg E., Tefferi A., Bloomfield C.D. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
3. Leone G., Pagano L., Ben-Yehuda D., Voso M.T. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007, 92:1389-1398.
4. Godley L.A., Larson R.A. Therapy-related myeloid leukemia. Semin. Oncol. 2008, 35:418-429.
5. Pedersen-Bjergaard J., Christiansen D.H., Desta F., Andersen M.K. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006, 20:1943-1949.
6. Pedersen-Bjergaard J., Andersen M.K., Andersen M.T., Christiansen D.H. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008, 22:240-248.
7. Le H., Singh S., Shih S.J., Du N., Schnyder S., Loredo G.A., Bien C., Michaelis L., Toor A., Diaz M.O., Vaughan A.T. Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. Genes Chromosomes Cancer 2009, 48:806-815.
8. Felix C.A., Kolaris C.P., Osheroff N. Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst.) 2006, 5:1093-1108.
9. Armstrong S.A., Staunton J.E., Silverman L.B., Pieters R., den Boer M.L., Minden M.D., Sallan S.E., Lander E.S., Golub T.R., Korsmeyer S.J. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 2002, 30:41-47.
10. Mistry A.R., Felix C.A., Whitmarsh R.J., Mason A., Reiter A., Cassinat B., Parry A., Walz C., Wiemels J.L., Segal M.R., Adès L., Blair I.A., Osheroff N., Peniket A.J., Lafage-Pochitaloff M., Cross N.C., Chomienne C., Solomon E., Fenaux P., Grimwade D. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N. Engl. J. Med. 2005, 352:1529-1538.
11. Hasan S.K., Mays A.N., Ottone T., Ledda A., La Nasa G., Cattaneo C., Borlenghi E., Melillo L., Montefusco E., Cervera J., Stephen C., Satchi G., Lennard A., Libura M., Byl J.A., Osheroff N., Amadori S., Felix C.A., Voso M.T., Sperr W.R., Esteve J., Sanz M.A., Grimwade D., Lo-Coco F. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008, 112:3383-3390.
12. Mays A.N., Osheroff N., Xiao Y., Wiemels J.L., Felix C.A., Byl J.A., Saravanamuttu K., Peniket A., Corser R., Chang C., Hoyle C., Parker A.N., Hasan S.K., Lo-Coco F., Solomon E., Grimwade D. Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood 2009, (Epub ahead of print).
13. Karran P., Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat. Rev. Cancer 2008, 8:24-36.
14. Offman J., Opelz G., Doehler B., Cummins D., Halil O., Banner N.R., Burke M.M., Sullivan D., Macpherson P., Karran P. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004, 104:822-828.
15. Lan Q., Zhang L., Li G., Vermeulen R., Weinberg R.S., Dosemeci M., Rappaport S.M., Shen M., Alter B.P., Wu Y., Kopp W., Waidyanatha S., Rabkin C., Guo W., Chanock S., Hayes R.B., Linet M., Kim S., Yin S., Rothman N., Smith M.T. Hematotoxicity in workers exposed to low levels of benzene. Science 2004, 306:1774-1776.
16. Haferlach C., Mecucci C., Schnittger S., Kohlmann A., Mancini M., Cuneo A., Testoni N., Rege-Cambrin G., Santucci A., Vignetti M., Fazi P., Martelli M.P., Haferlach T., Falini B. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 2009, 114:3024-3032.
17. Falini B. Therapy-related acute myeloid leukaemia with mutated NPM1: treatment induced or de novo in origin?. Leukemia 2008, 22:891-892.
18. Bacher U., Haferlach T., Kern W., Haferlach C., Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007, 92:744-752.
19. Delwail V., Jais J.P., Colonna P., Andrieu J.M. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br. J. Haematol. 2002, 118:189-194.
20. Brusamolino E., Baio A., Orlandi E., Arcaini L., Passamonti F., Griva V., Casagrande W., Pascutto C., Franchini P., Lazzarino M. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin. Cancer Res. 2006, 12:6487-6793.
21. Engert A., Diehl V., Franklin J., Lohri A., Dörken B., Ludwig W.D., Koch P., Hänel M., Pfreundschuh M., Wilhelm M., Trümper L., Aulitzky W.E., Bentz M., Rummel M., Sezer O., Müller-Hermelink H.K., Hasenclever D., Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 Study. J. Clin. Oncol. 2009, 27:4548-4554.
22. Sacchi S., Marcheselli L., Bari A., Marcheselli R., Pozzi S., Luminari S., Lombardo M., Buda G., Lazzaro A., Gobbi P.G., Stelitano C., Morabito F., Quarta G., Brugiatelli M. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008, 93:398-404.
23. Leleu X., Soumerai J., Roccaro A., Hatjiharissi E., Hunter Z.R., Manning R., Ciccarelli B.T., Sacco A., Loakimidis L., Adamia S., Moreau A.S., Patterson C.J., Ghobrial I.M., Treon S.P. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J. Clin. Oncol. 2009, 27:250-255.
24. Mudie N.Y., Swerdlow A.J., Higgins C.D., Smith P., Qiao Z., Hancock B.W., Hoskin P.J., Linch D.C. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J. Clin. Oncol. 2006, 24:1568-1574.
25. Gyan E., Foussard C., Bertrand P., Michenet P., Le Gouill S., Berthou C., Maisonneuve H., Delwail V., Gressin R., Quittet P., Vilque J.P., Desablens B., Jaubert J., Ramée J.F., Arakelyan N., Thyss A., Moluçon-Chabrot C., Delépine R., Milpied N., Colombat P., Deconinck E. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009, 113:995-1001. Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS).
26. Chakraborty S., Sun C.L., Francisco L., Sabado M., Li L., Chang K.L., Forman S., Bhatia S., Bhatia R. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J. Clin. Oncol. 2009, 27:791-798.
27. Hijiya N., Hudson M.M., Lensing S., Zacher M., Onciu M., Behm F.G., Razzouk B.I., Ribeiro R.C., Rubnitz J.E., Sandlund J.T., Rivera G.K., Evans W.E., Relling M.V., Pui C.H. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007, 297:1207-1215.
28. Praga C., Bergh J., Bliss J., Bonneterre J., Cesana B., Coombes R.C., Fargeot P., Folin A., Fumoleau P., Giuliani R., Kerbrat P., Hery M., Nilsson J., Onida F., Piccart M., Shepherd L., Therasse P., Wils J., Rogers D. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and Cyclophosphamide. J. Clin. Oncol. 2005, 23:4179-4191.
29. Martin M.G., Welch J.S., Luo J., Ellis M.J., Graubert T.A., Walter M.J. Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res. Treat. 2009 Dec, 118(3):593-598.
30. Seedhouse C., Russell N. Advances in the understanding of susceptibility to treatment related acute myeloid leukaemia. Br. J. Haemat. 2007, 137:513-529.
31. Guillem V., Tormo M. Influence of DNA damage and repair upon the risk of treatment related leukemia. Leuk. Lymphoma 2008, 49:204-217.
32. Bolufer P., Collado M., Barragan E., Calasanz M.J., Colomer D., Tormo M., González M., Brunet S., Batlle M., Cervera J., Sanz M.A. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br. J. Haematol. 2007, 136:590-596.
33. Felix C.A., Walker A.H., Lange B.J., Williams T.M., Winick N.J., Cheung N.K., Lovett B.D., Nowell P.C., Blair I.A., Rebbeck T.R. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. U.S.A 1998, 95:13176-13181.
34. Rund D., Krichevsky S., Bar-Cohen S., Goldschmidt N., Kedmi M., Malik E., Gural A., Shafran-Tikva S., Ben-Neriah S., Ben-Yehuda D. Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia 2005, 19:1919-1928.
35. Voso M.T., Fabiani E., D'Alo' F., Guidi F., Di Ruscio A., Sica S., Pagano L., Greco M., Hohaus S., Leone G. Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Ann. Oncol. 2007, 18:1523-1528.
36. Larson R.A., Wang Y., Banerjee M., Wiemels J., Hartford C., Le Beau M.M., Smith M.T. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999, 94:803-807.
37. Naoe T., Takeyama K., Yokozawa T., Kiyoi H., Seto M., Uike N., Ino T., Utsunomiya A., Maruta A., Jin-nai I., Kamada N., Kubota Y., Nakamura H., Shimazaki C., Horiike S., Kodera Y., Saito H., Ueda R., Wiemels J., Ohno R. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin. Cancer Res. 2000, 6:4091-4095.
38. Allan J.M., Wild C.P., Rollinson S., Willett E.V., Moorman A.V., Dovey G.J., Roddam P.L., Roman E., Cartwright R.A., Morgan G.J. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:11592-11597.
39. Seedhouse C., Faulkner R., Ashraf N., Das-Gupta E., Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin. Cancer Res. 2004, 10:2675-2680.
40. Smith A.G., Worrillow L.J., Allan J.M. A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia. Blood 2007, 109:1233-1236.
41. Worrillow L.J., Smith A.G., Scott K., Andersson M., Ashcroft A.J., Dores G.M., Glimelius B., Holowaty E., Jackson G.H., Jones G.L., Lynch C.F., Morgan G., Pukkala E., Scott D., Storm H.H., Taylor P.R., Vyberg M., Willett E., Travis L.B., Allan J.M. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J. Med. Genet. 2008, 45:142-146.
42. Schwartz C.L., Constine L.S., Villaluna D., London W.B., Hutchison R.E., Sposto R., Lipshultz S.E., Turner C.S., de Alarcon P.A., Chauvenet A. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 2009, 114:2051-2059.
43. Morrison V.A., Rai K.R., Peterson B.L., Kolitz J.E., Elias L., Appelbaum F.R., Hines J.D., Shepherd L., Larson R.A., Schiffer C.A. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J. Clin. Oncol. 2002, 20:3878-3884.
44. Tam C.S., O'Brien S., Wierda W., Kantarjian H., Wen S., Do K.A., Thomas D.A., Cortes J., Lerner S., Keating M.J. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975-980.
45. Löning L., Zimmermann M., Reiter A., Kaatsch P., Henze G., Riehm H., Schrappe M. Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000, 95:2770-2775.
46. Schmiegelow K., Al-Modhwahi I., Andersen M.K., Behrendtz M., Forestier E., Hasle H., Heyman M., Kristinsson J., Nersting J., Nygaard R., Svendsen A.L., Vettenranta K., Weinshilboum R. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood 2009, 113:6077-6084. Nordic Society for Paediatric Haematology and Oncology.
47. Stanulla M., Schaeffeler E., Möricke A., Coulthard S.A., Cario G., Schrauder A., Kaatsch P., Dördelmann M., Welte K., Zimmermann M., Reiter A., Eichelbaum M., Riehm H., Schrappe M., Schwab M. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols. Blood 2009, 114:1314-1318.
48. Bernard-Marty C., Mano M., Paesmans M., Accettura C., Munoz-Bermeo R., Richard T., Kleiber K., Cardoso F., Lobelle J.P., Larsimont D., Piccart M.J., Di Leo A. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. Ann. Oncol. 2003, 14:693-698.
49. Smith R.E., Bryant J., DeCillis A., Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J. Clin. Oncol. 2003, 21:1195-1204. National Surgical Adjuvant Breast and Bowel Project Experience.
50. Hershman D., Neugut A.I., Jacobson J.S., Wang J., Tsai W.Y., McBride R., Bennett C.L., Grann V.R. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J. Natl. Cancer Inst. 2007, 99:196-205.